Actively Recruiting
Augmented Bladder Tumor Detection Using the Bladder-Portable Artifact Detection System: A Multicentric Prospective Analytic Study Using Real Time Based Artificial Intelligence
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2022-07-15
500
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new method to improve the diagnosis and monitoring of bladder tumors by combining traditional bladder endoscopy with an artificial intelligence (AI) based diagnostic tool called the Bladder-Portable Artifact Detection System (Bladder-PAD). The study aims to reduce diagnostic errors and standardize tumor descriptions to better characterize tumor aggressiveness and improve patient care. This observational study is led by the Centre Hospitalier Universitaire, Amiens. The study uses video frames extracted from a dataset of cystoscopy videos, which are then analyzed using a pre-trained convolutional neural network model with feature detection algorithms. The Bladder-PAD system will be assessed for its ability to detect bladder tumors and predict the risk of tumor recurrence and progression compared to standard white light cystoscopy. Participants will undergo cystoscopy examinations where tumor detection rates and false detection rates will be measured for both white light cystoscopy and Bladder-PAD cystoscopy on the same day. Data analysis will occur at both patient and lesion levels to evaluate the accuracy of the AI system. The study involves no treatment intervention but focuses on diagnostic performance, aiming to develop a precise diagnostic companion tool for bladder tumor management.
CONDITIONS
Brief Title
Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Unifocal primary or recurrent suspected bladder cancer with tumor size less or equal than 3 cm
- Multifocal primary or recurrent suspected bladder cancer with 5 or fewer lesions and each tumor size less or equal than 3 cm
- Age 18 years or older
You will not qualify if you...
- More than 5 tumors or any tumor larger than 3 cm
- Suspected muscle-invasive bladder cancer (cT2 or higher) based on computed tomography or cystoscopy
- Evidence of distant metastases on computed tomography or magnetic resonance imaging
- Gross hematuria
- Bacillus Calmette-Guerin (BCG) treatment or chemotherapy within 3 months prior to inclusion, except a single course immediately following TUR
- Patients who do not consent to the use of their data for research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo cystoscopy procedures using white light and Bladder-PAD cystoscopy to detect bladder tumors.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Amiens University Hospital
Amiens, France, 80054
Actively Recruiting
Research Team
F
Fabien SAINT, Pr
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here